lilly tirzepatide trial New clinical trial: Zepbound (tirzepatide) helped adults lose an average of 20.2% of their body weight—around 50 lbs—over 72 weeks, outperforming Wegovy's 13.7% (~33 lbs). Credit to: https://www.healthline.com/health-news/zepbound-wegovy-weight-loss Latest Data From SURPASS Trials

Starting self-pay rates for Foundayo begin at $149 per month, and we work to locate the lowest possible cost for oral Wegovy

South African pharmaceutical company Aspen has secured regulatory approval to market Mounjaro for chronic weight management, positioning the local manufacturer to compete in the rapidly expanding global market for weight-loss medications

It is now appreciated that multiple regions within the hypothalamus, brainstem, and beyond, transduce pharmacological GLP-1R-dependent signals in the brain to reduce food intake, enabling weight loss with chronic administration of GLP-1RA (1)

Plasma is used in a number of ways in medicine

Retatrutide ought to become part of a larger strategy, not a quick fix, particularly for men with multifaceted health requirements

Inclusion in a development programme means a question is being tested